The approval and commercialization of Oxervate (cenegermin-bkbj, Dompé) in the United States has improved our ability to treat corneal persistent epithelial defects (PEDs) or corneal ...

The company is evaluating ST266 in multiple indications including ophthalmic conditions such as optic neuritis, glaucoma and persistent corneal epithelial defects (PEDs). Noveome uses targeted ...

On the left eye, the patient had conjunctival congestion and hyperemia, a central 2- × 2-mm corneal epithelial defect with deep stromal infiltration, endothelial plaque, moderate anterior chamber ...

Kala Pharmaceuticals Inc (NASDAQ:KALA)., a micro-cap biotech company valued at $40.13 million, has seen its stock reach a 52-week high, hitting an impressive $8.81. This peak reflects a significant ...